The NanoNautilus : A Breakthrough In The Successful Treatment Of Strokes And Other Cerebrovascular Diseases
Funder
National Health and Medical Research Council
Funding Amount
$187,212.00
Summary
Strokes are one of the biggest killers of Australians and are becoming increasingly so every year. Bleeding from the brain involves extremely delicate and dangerous medical treatments. The development of NanoNautilus [TM]---a remote-controlled steerable microcatheterusing world-first miniaturization technology---will revolutionise current practises and greatly reduce the current risk with medical intervention.
Development Of A Humanised Antibody For Treatment Of Cancer And Stroke
Funder
National Health and Medical Research Council
Funding Amount
$400,142.00
Summary
The protein PDGF-CC has a critical role in blood vessel development, and is implicated in the development of cancer, and the debilitating consequences of acute stroke. Researchers in the Ludwig Institute for Cancer Research have developed novel anti-PDGF-CC antibodies. The research program proposed will generate data and clinical reagents that will enable a lead candidate anti-PDGF-CC antibody to be commercialised, and ultimately evaluated clinically in cancer and stroke patients.
Development Of Platelet-Targeted Nanoparticles For Magnetic Resonance Imaging Towards The Detection Of Thrombi/Emboli And Vulnerable Atherosclerotic Plaques
Funder
National Health and Medical Research Council
Funding Amount
$606,524.00
Summary
Heart attack, stroke and pulmonary embolism typically strike without warning and either kill patients or cause devastating disabilities. Currently, we do not have diagnostic methods to identify patients and the blood vessels at risk. We have developed a new innovative MRI nanoparticle directed against activated platelets for the detection of _at risk� blood vessels. The current funding is requested to optimise the manufacture of this targeted MRI nanoparticle and to undertake the animal studies ....Heart attack, stroke and pulmonary embolism typically strike without warning and either kill patients or cause devastating disabilities. Currently, we do not have diagnostic methods to identify patients and the blood vessels at risk. We have developed a new innovative MRI nanoparticle directed against activated platelets for the detection of _at risk� blood vessels. The current funding is requested to optimise the manufacture of this targeted MRI nanoparticle and to undertake the animal studies required to enter early stage clinical trials.Read moreRead less